[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,926
  • Shares Outstanding, K 65,351
  • Annual Sales, $ 10,330 K
  • Annual Income, $ -129,770 K
  • EBIT $ -129 M
  • EBITDA $ -126 M
  • 60-Month Beta 1.04
  • Price/Sales 6.65
  • Price/Cash Flow N/A
  • Price/Book 0.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 3
  • High Estimate $-0.21
  • Low Estimate $-0.44
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8251 +52.71%
on 06/25/26
1.2800 -1.56%
on 07/08/26
+0.2661 (+26.77%)
since 06/08/26
3-Month
0.8251 +52.71%
on 06/25/26
1.4700 -14.29%
on 04/20/26
+0.2000 (+18.87%)
since 04/08/26
52-Week
0.8251 +52.71%
on 06/25/26
2.5700 -50.97%
on 10/16/25
-0.4400 (-25.88%)
since 07/08/25

Most Recent Stories

More News
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHAâ„¢ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be...

TCRX : 1.2600 (+17.76%)
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Early data on patients treated in Cohort C of the ALLOHAâ„¢ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 â„¢ ) planned for the second...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA â„¢ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHAâ„¢ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.2600 (+17.76%)
TScan Therapeutics Announces Positive Updated Data from the ALLOHAâ„¢ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up...

TCRX : 1.2600 (+17.76%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.6000
2nd Resistance Point 1.4400
1st Resistance Point 1.3500
Last Price 1.2600
1st Support Level 1.1000
2nd Support Level 0.9400
3rd Support Level 0.8500

See More

52-Week High 2.5700
Fibonacci 61.8% 1.9034
Fibonacci 50% 1.6975
Fibonacci 38.2% 1.4917
Last Price 1.2600
52-Week Low 0.8251

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.